更新于：2024-11-01

Merck Sharp & Dohme SA

子公司|

Morocco

子公司|

Morocco

更新于：2024-11-01

概览

关联

项与 Merck Sharp & Dohme SA 相关的临床试验

EUCTR2007-002218-21-IT / Not yet recruitingN/A

A Phase III Randomized, Active-Comparator (Pioglitazone) Controlled Clinical Trial toStudy the Efficacy and Safety of Sitagliptin and MK-0431A (A Fixed-Dose CombinationTablet of Sitagliptin and Metformin) in Patients With Type 2 Diabetes Mellitus - ND

开始日期2007-12-03

申办/合作机构

Merck Sharp & Dohme SA

EUCTR2006-005101-64-IT / Not yet recruiting临床3期

A Randomized, Placebo-Controlled Study to Evaluate the Safety, Efficacy and Mechanism of Action of MK-0431/Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - ND

开始日期2007-11-28

申办/合作机构

Merck Sharp & Dohme SA

EUCTR2006-005051-15-IT / Not yet recruiting临床3期

A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK-0431) to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or in Combination With Metformin) - ND

开始日期2007-11-05

申办/合作机构

Merck Sharp & Dohme SA

100 项与 Merck Sharp & Dohme SA 相关的临床结果

登录后查看更多信息

0 项与 Merck Sharp & Dohme SA 相关的专利（医药）

登录后查看更多信息

项与 Merck Sharp & Dohme SA 相关的文献（医药）

2019-06-01·Rheumatology International4区 · 医学

Discordance between doctor and patient assessments and non-adherence to subcutaneous biological drugs

4区 · 医学

Article

作者: Cea-Calvo, Luis ; Carmona, Loreto ; Otón, Teresa ; Arteaga, Maria J ; Calvo-Alén, Jaime ; Urruticoechea-Arana, Ana

To estimate the agreement level between patient and physician assessment of disease activity and to explore whether agreement is associated with adherence to subcutaneous (SC) biological drugs in rheumatoid arthritis (RA). Cross-sectional study of RA patients who had been prescribed a SC biological drug in the past 12-18 months was performed. Patients and physicians global disease activity on visual analogue scale (VAS) were collected. Disagreement was defined as an absolute difference ≥ 3 points between VAS scores. Adherence was assessed by the Medication Possession Ratio (MPR), considering adherence an MPR > 80%. We analysed 360 patients of whom 15.5% presented disagreement with their physicians. The mean patient global VAS was 5.75 ± 1.8 (median 5.5 [5-7]) in the disagreement group versus 2.7 ± 2.2 (median 2 [1-4]) in the agreement group (p < 0.001). There were also differences in physicians global VAS between groups (p = 0.01). The non-adherence to SC biological drugs rate was 10.7% and 14.5% in the disagreement and agreement groups (p = 0.45). No association between adherence and discordance was found. Disagreement in the global disease activity between patients and physicians was detected in 15.5% of patients. In general, patients perceived higher disease activity. No associations between patient-physician disagreement in VAS and adherence were observed.

2018-09-01·Rheumatology International4区 · 医学

Correction to: The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern

4区 · 医学

Article

作者: Salman-Monte, Tarek C ; Carmona, Loreto ; Raya, Enrique ; Fernandez, Sabela ; Marras, Carlos ; Arteaga, Maria J ; Calvo-Alén, Jaime ; Ortiz, Ana ; Monteagudo, Indalecio ; Cea-Calvo, Luis ; Salvador, Georgina

In the original publication, the family name of the last author was incorrect. The correct name should read as Jaime Calvo-Alén.

2018-09-01·Rheumatology International4区 · 医学

The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern

4区 · 医学

Article

作者: Salman-Monte, Tarek C ; Carmona, Loreto ; Raya, Enrique ; Calvo-Allén, Jaime ; Fernandez, Sabela ; Marras, Carlos ; Arteaga, Maria J ; Ortiz, Ana ; Monteagudo, Indalecio ; Cea-Calvo, Luis ; Salvador, Georgina

Patients' beliefs about their prescribed medication are an important factor influencing intentional non-adherence. This study describes rheumatoid arthritis (RA) patients' beliefs about their subcutaneous (SC) biological medication through the Beliefs about Medicines Questionnaire (BMQ), and potential associations. As part of the ARCO study (Study on Adherence of Rheumatoid arthritis patients to subCutaneous and Oral drugs), patients completed the BMQ specifically for their SC biological medication, encompassing a necessity and a concerns scale. The medication possession ratio (MPR) was calculated to assess adherence to the SC biological medication. The BMQ was completed by 321 patients. Between 71.0 and 89.7% of patients agreed/strongly agreed with necessity scale statements, and only 7.2% had low necessity scores. Between 20.0 and 49.8% of patients agreed/strongly agreed with four of five concern scale statements, and 72.3% agreed/strongly agreed with the concern statement regarding long-term medication effects. The percentage with high concerns was 58.9%, and was higher in patients not satisfied with, or with less fulfillment of, tolerability expectations. Non-adherence percentages were, respectively, 13.8 and 13.0% (p = 0.919) in those with high or low necessity, and 16.0 and 10.6% (p = 0.171) in those with high or low concerns. Most patients were categorized as 'ambivalent' (58.5%; high necessity/high concerns) or 'accepting' (36.1%; high necessity/low concerns) of their SC biological medication. The BMQ identified patients' concerns with their SC biological medication. Because patients' concerns could influence non-adherence to medication and future outcomes, physicians should address this issue in the clinic by informing patients and setting clear expectations.

100 项与 Merck Sharp & Dohme SA 相关的药物交易

登录后查看更多信息

100 项与 Merck Sharp & Dohme SA 相关的转化医学

登录后查看更多信息